Alnylam Pharmaceuticals, Inc. Website

Alnylam Pharmaceuticals, Inc.

NasdaqGS-ALNY

Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

  • Name

    Alnylam Pharmaceuticals, Inc.

  • CEO

    Yvonne L. Greenstreet

  • Website

    www.alnylam.com

  • Sector

    Biotechnology

  • Year Founded

    2002

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Alnylam's Nobel-prize-winning technology and massive intellectual property in RNA interference helped the firm create an entirely new class of therapeutics for difficult to treat diseases.

  • Alnylam's full pipeline offers several opportunities to bolster the company's competitive position, and it indicates a reproducible research strategy.

  • Onpattro is the first approved RNA interference therapy. In addition to first-mover advantage, Alnylam is positioned to expand its reach in ATTR amyloidosis with next-generation Amvuttra, which is administered less frequently.

Bears Say

  • Alnylam's valuation rests on its ability to maintain six-figure pricing and payers' willingness to continue reimbursement, which could be affected by shifts in healthcare drug policy.

  • While Alnylam is targeting several rare genetic disorders—including amyloidosis, AHP, and complement-mediated diseases—entrenched competitors are also progressing next-generation treatments.

  • As is the case with most orphan diseases, if Alnylam cannot successfully raise awareness of these underdiagnosed diseases and improve diagnosis rates, its commercial success will be limited.

Source: Morningstar Analysis - Oct 31, 2025

What's happening

Nov 5, 2025 - Dec 5, 2025

Alnylam Pharmaceuticals Sees Strong Gains Amid Leadership Changes and Product Success

  • Significant board changes, including the appointment of Stuart Arbuckle, are expected to enhance Alnylam's growth prospects.
  • Positive expert insights on RNA interference therapeutics bolster investor confidence in Alnylam's competitive position.
  • Revenue from AMVUTTRA® continues to show strong year-over-year growth, reinforcing market optimism.

Over the past month, Alnylam Pharmaceuticals (ALNY) experienced a notable increase of 11.8% in its stock price. This performance significantly outpaced the S&P 500’s return of 1.3%, reflecting strong investor sentiment driven by key developments within the company and its strategic direction.

A major catalyst for ALNY's positive momentum was the announcement regarding significant changes to its board of directors on December 3rd. The departure of long-serving members Mike Bonney and Carolyn Bertozzi coincided with the appointment of Stuart Arbuckle as an independent director effective January 2026. Arbuckle brings extensive experience from Vertex Pharmaceuticals, which is anticipated to positively influence Alnylam’s growth trajectory.

Additionally, discussions surrounding therapeutic advancements have been favorable for ALNY. On December 2nd, insights from a Key Opinion Leader indicated that stabilizers would continue dominating first-line treatment options in cardiovascular genetics—a sector where Alnylam is actively engaged through RNA interference therapeutics. This expert opinion reinforced investor confidence regarding ALNY’s competitive positioning in this expanding field.

Despite earlier bearish sentiments linked to insider transactions and mixed clinical data presentations in November, Alnylam maintained upward pressure on its stock price through consistent revenue announcements tied to their cardiomyopathy treatment AMVUTTRA®. Reports indicated that AMVUTTRA generated $300 million in revenue during Q3 alone and has seen substantial sales increases year-over-year.

Overall, while moments of uncertainty related to competition and internal transitions existed throughout this month, positive news flow concerning leadership changes and product performance helped solidify investor confidence around ALNY's future potential. Ultimately, Alnylam Pharmaceuticals Inc outperformed not only the Health Care (XLV) sector by 5.7%, but also demonstrated resilience against broader market trends reflected by S&P index movements during this period.

NasdaqGS:ALNY